{
    "4 24 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain positive [\u2026]",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Insider Monkey",
                "ticker": "INSM",
                "title": "Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying",
                "url": "https://finance.yahoo.com/news/insmed-incorporated-insm-among-takeover-004658190.html"
            },
            {
                "headline": "Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes Due 2028 (the \"Notes\") (CUSIP No. 457669AB5) for redemption on June 6, 2025 (the \"Redemption Date\"). Insmed is redeeming the Notes as permitted under Section 11",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3612",
                "source": "PR Newswire",
                "ticker": "INSM",
                "title": "Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028",
                "url": "https://finance.yahoo.com/news/insmed-announces-redemption-569-5-110000526.html"
            },
            {
                "headline": "Insmed (INSM) said Thursday it will redeem June 6 the entire $569.5 million aggregate principal amou",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "INSM",
                "title": "Insmed to Redeem $569.5 Million of Convertible Senior Notes",
                "url": "https://finance.yahoo.com/news/insmed-redeem-569-5-million-142722935.html"
            },
            {
                "headline": "Insmed (INSM) said Thursday it will redeem June 6 the entire $569.5 million aggregate principal amou",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "INSM",
                "title": "Insmed to Redeem $569.5 Million of Convertible Senior Notes",
                "url": "https://finance.yahoo.com/news/insmed-redeem-569-5-million-142722935.html"
            },
            {
                "headline": "Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes Due 2028 (the \"Notes\") (CUSIP No. 457669AB5) for redemption on June 6, 2025 (the \"Redemption Date\"). Insmed is redeeming the Notes as permitted under Section 11",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3612",
                "source": "PR Newswire",
                "ticker": "INSM",
                "title": "Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028",
                "url": "https://finance.yahoo.com/news/insmed-announces-redemption-569-5-110000526.html"
            },
            {
                "headline": "We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain positive [\u2026]",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Insider Monkey",
                "ticker": "INSM",
                "title": "Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying",
                "url": "https://finance.yahoo.com/news/insmed-incorporated-insm-among-takeover-004658190.html"
            }
        ],
        "avgScore": 0.4055666666666667,
        "pctChange": 0.010585895687721444
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM). The landmark ASPEN study is the largest clinical trial ever conducted in bronchiectasis, a seriou",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "PR Newswire",
                "ticker": "INSM",
                "title": "New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis",
                "url": "https://finance.yahoo.com/news/england-journal-medicine-publishes-positive-210000836.html"
            },
            {
                "headline": "Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0772",
                "source": "PR Newswire",
                "ticker": "INSM",
                "title": "Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025",
                "url": "https://finance.yahoo.com/news/insmed-host-first-quarter-2025-110000143.html"
            },
            {
                "headline": "Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0772",
                "source": "PR Newswire",
                "ticker": "INSM",
                "title": "Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025",
                "url": "https://finance.yahoo.com/news/insmed-host-first-quarter-2025-110000143.html"
            },
            {
                "headline": "Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM). The landmark ASPEN study is the largest clinical trial ever conducted in bronchiectasis, a seriou",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "PR Newswire",
                "ticker": "INSM",
                "title": "New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis",
                "url": "https://finance.yahoo.com/news/england-journal-medicine-publishes-positive-210000836.html"
            }
        ],
        "avgScore": 0.2401,
        "pctChange": -0.02598875547985549
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders with [\u2026]",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Insider Monkey",
                "ticker": "INSM",
                "title": "Is Insmed Incorporated\u00a0(INSM) the Best Long Term Growth Stock to Buy According to Billionaires?",
                "url": "https://finance.yahoo.com/news/insmed-incorporated-insm-best-long-180956506.html"
            },
            {
                "headline": "We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders with [\u2026]",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Insider Monkey",
                "ticker": "INSM",
                "title": "Is Insmed Incorporated\u00a0(INSM) the Best Long Term Growth Stock to Buy According to Billionaires?",
                "url": "https://finance.yahoo.com/news/insmed-incorporated-insm-best-long-180956506.html"
            }
        ],
        "avgScore": 0.9274,
        "pctChange": 0.0397106631149724
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 20 Stocks Insiders Were Selling In Q1 2025. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other stocks insiders were selling in Q1 2025. The broader market index rose 0.2% on Tuesday amid volatility as investors awaited clarity on President Trump\u2019s tariff [\u2026]",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Insider Monkey",
                "ticker": "INSM",
                "title": "Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025",
                "url": "https://finance.yahoo.com/news/insmed-incorporated-insm-insiders-were-135053000.html"
            },
            {
                "headline": "We recently published a list of 20 Stocks Insiders Were Selling In Q1 2025. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other stocks insiders were selling in Q1 2025. The broader market index rose 0.2% on Tuesday amid volatility as investors awaited clarity on President Trump\u2019s tariff [\u2026]",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Insider Monkey",
                "ticker": "INSM",
                "title": "Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025",
                "url": "https://finance.yahoo.com/news/insmed-incorporated-insm-insiders-were-135053000.html"
            }
        ],
        "avgScore": 0.3818,
        "pctChange": -0.001497829611856644
    },
    "coef": 1.0,
    "avgCoef": -0.012748782778689356,
    "similar": {
        "CMCSA": 1.0,
        "NOK": 1.0,
        "JD": 1.0,
        "INSM": 1.0
    }
}